At the 2023 SAN Antonio Breast Cancer Seminar (SABCS), Luca Gianni introduced the PD-L1 inhibitor atezolizumab to HP NATs, thus verifying the feasibility of improving the efficacy of NATs for treating HER2+ BC by modulating the immune system (Gianni et al.). Here, ERBB2 is linked to breast carcinoma.